

Internet Search & Sustainability Analysis Agent

General Query

Ask the agent anything:

Have you run any analysis yet?

Submit Query

Sustainability Report Analysis

Enter industry name to analyze:

pharma

Start Analysis

Analysis task submitted successfully! Task ID: 4313fac6-5ddf-4e4e-8607-7ed915b826a1

Status will update below automatically (polling every 10s).

Analysis Status for 'pharma' (Task ID: 4313fac6-5ddf-4e4e-8607-7ed915b826a1)

Status: COMPLETED (Duration: 175 seconds)

Analysis Result:

Analysis based on reports processed for:

- Eli Lilly: https://assets.ctfassets.net/1o78rkhl3da6/2orku5xchhldzA1nJC7dDF/ed94f586bbde3f635a1302a4c0b2b198/Lilly_2022_Sustainability_Bond_Allocation_Report_Final_8.24.23.pdf
- Novartis: https://www.novartis.com/sites/novartis_com/files/novartis-q4-2023-impact-and-sustainability-update.pdf
- Pfizer: https://cdn.pfizer.com/pfizercom/Pfizer_2023_ESG_Performance_13MAR2024.pdf
- Roche: <https://assets.roche.com/f/176343/x/98b8e2ba9d/ar23e.pdf>
- Merck & Co.: https://www.merckgroup.com/en/sustainability-report/2023/_assets/downloads/entire-merck-sr23.pdf
- AbbVie: <https://www.abbvie.com/content/dam/abbvie-com2/pdfs/esg-disclosure-supplement.pdf>

--- Synthesized Trends --- Based *only* on the provided summaries, the main sustainability trends, common themes, and notable differences across these pharma companies (excluding AbbVie, for which no data was provided) are:

Common Themes & Trends:

1. Ambitious Climate Action & Emissions Reduction:

- **Net-Zero Goals:** Most companies (Novartis, Pfizer, Roche, Merck & Co.) have set Net-Zero emissions targets, typically for 2040 or 2050.
- **Science-Based Targets (SBTi):** Alignment with SBTi is common (Novartis, Pfizer, Roche, Merck & Co.) for emissions reduction goals.
- **Focus on Scope 1 & 2:** All reporting companies are targeting significant reductions in their direct operational emissions.
- **Increasing Scope 3 Focus:** Several companies (Novartis, Pfizer, Merck & Co.) are also addressing value chain emissions, particularly through supplier engagement.

2. Transition to Renewable Electricity:

- A strong push towards 100% renewable electricity usage is evident, with targets set around 2025-2030 (Novartis, Pfizer, Roche, Merck & Co.).

3. Water Stewardship & Waste Reduction:

- Efforts to reduce water consumption and waste generation are consistently reported, often with specific percentage reduction targets against a baseline year (Eli Lilly, Novartis, Pfizer, Roche, Merck & Co.).
- Some mention "water neutrality" (Novartis) or circular economy principles (Eli Lilly, Roche, Merck & Co.).

4. Supply Chain Sustainability:

- Integrating ESG criteria into supply chain management is a key trend. This includes environmental screening/criteria for suppliers (Novartis, Pfizer, Roche, Merck & Co.) and addressing social risks like human rights, child/forced labor (Pfizer, Roche, Merck & Co.).

5. Patient Access & Global Health:

- A core social priority for all reporting companies is improving access to medicines and healthcare, particularly in Low- and Middle-Income Countries (LMICs) and for underserved populations (Eli Lilly, Novartis, Pfizer, Roche, Merck & Co.). This often involves specific patient reach goals or R&D investment in neglected diseases.

6. Diversity, Equity & Inclusion (DE&I):

- DE&I initiatives are highlighted, with companies reporting on metrics like gender representation in management and pay equity, or setting future targets (Eli Lilly, Novartis, Pfizer, Roche, Merck & Co.).

7. Robust ESG Governance & Reporting:

- Companies emphasize the integration of ESG into their core business strategy and governance structures, often with board-level oversight and dedicated committees (Eli Lilly, Novartis, Pfizer, Roche, Merck & Co.).
- Alignment with major reporting frameworks (GRI, SASB, TCFD, UN SDGs) is standard practice.
- Third-party verification or assurance for ESG data/reports is also mentioned by several (Eli Lilly, Roche, Merck & Co.).

8. Human Rights:

- Upholding human rights across operations and supply chains is a stated commitment, often involving due diligence, risk assessments, and grievance mechanisms (Novartis, Pfizer, Roche, Merck & Co.).

Notable Differences or Specific Mentions:

- **Sustainability Bonds:** Eli Lilly and Pfizer specifically mention the use of Sustainability Bonds to

fund environmental and social projects.

- **Specific "Neutrality" Goals:** Novartis has explicit targets for "Plastic Neutrality" and "Water Neutrality" by 2030.
- **"Real Zero":** Roche uniquely refers to its 2050 emissions goal as "real zero," potentially indicating a stricter approach to offsets.
- **Biodiversity Focus:** Novartis explicitly mentions assessing biodiversity for a strategy.
- **KPIs Linked to Compensation:** Pfizer explicitly notes that ESG KPIs are linked to leadership compensation; Roche also mentions ESG linkage to remuneration.
- **Animal Testing Reduction:** Roche specifically highlights efforts to reduce reliance on animal testing.
- **Impact Framework:** Eli Lilly details an "impact framework" covering 15 key ESG topics.

No Information Available:

- **AbbVie:** No ESG information was available from the provided summary.